2 weeks Ago By ABMN Staff
Legal & General Group Plc lessened its stake in shares of Denali Therapeutics Inc. ( NASDAQ:DNLI – Free Report ) by 4.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission.
The firm owned 149,513 shares of the company’s stock after selling 6,483 shares during the period. Legal & General Group Plc owned about 0.10% of Denali Therapeutics worth $3,047,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of DNLI. PNC Financial Services Group Inc. raised its holdings in shares of Denali Therapeutics by 30.
5% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company’s stock valued at $77,000 after acquiring an additional 885 shares during the period.
KBC Group NV raised its stake in Denali Therapeutics by 75.8% during the 4th quarter. KBC Group NV now owns 6,334 shares of the company’s stock valued at $129,000 after purchasing an additional 2,731 shares during the period.
AlphaQuest LLC lifted its holdings in shares of Denali Therapeutics by 177.1% in the fourth quarter. AlphaQuest LLC now owns 6,961 shares of the company’s stock valued at $142,000 after purchasing an additional 4,449 shares in the last quarter.
E Fund Management Co. Ltd. boosted its position in shares of Denali Therapeutics by 32.
2% in the fourth quarter. E Fund Management Co. Ltd.
now owns 9,997 shares of the company’s stock worth $204,000 after buying an additional 2,436 shares during the period. Finally, SG Americas Securities LLC grew its holdings in shares of Denali Therapeutics by 128.8% during the fourth quarter.
SG Americas Securities LLC now owns 11,003 shares of the company’s stock valued at $224,000 after buying an additional 6,195 shares in the last quarter. 92.92% of the stock is owned by hedge funds and other institutional investors.
Denali Therapeutics Stock Performance NASDAQ DNLI opened at $14.88 on Thursday. The stock has a market capitalization of $2.
16 billion, a PE ratio of -5.39 and a beta of 1.58.
The stock has a 50-day simple moving average of $15.21 and a 200 day simple moving average of $21.02.
Denali Therapeutics Inc. has a twelve month low of $10.57 and a twelve month high of $33.
33. Analyst Ratings Changes Several analysts recently commented on DNLI shares. B.
Riley restated a “buy” rating and set a $35.00 price target (down from $38.00) on shares of Denali Therapeutics in a report on Wednesday, March 5th.
Baird R W upgraded shares of Denali Therapeutics to a “strong-buy” rating in a report on Tuesday, January 7th. William Blair reiterated an “outperform” rating on shares of Denali Therapeutics in a report on Friday, February 28th. The Goldman Sachs Group lowered their target price on Denali Therapeutics from $45.
00 to $40.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. Finally, Robert W.
Baird began coverage on Denali Therapeutics in a report on Tuesday, January 7th. They set an “outperform” rating and a $31.00 price target for the company.
One equities research analyst has rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $37.57.
Check Out Our Latest Analysis on DNLI Denali Therapeutics Company Profile ( Free Report ) Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Read More Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
